Abstract:Background Current immunotherapies still have limited successful rates among cancers. It is now recognized that T cell functional state in the tumor microenvironment (TME) is a key determinant for effective antitumor immunity and immunotherapy. In addition to exhaustion, cellular senescence in tumor-infiltrating T cells (TILs) has recently been identified as an important T cell dysfunctional state induced by various malignant tumors. Therefore, a better understanding of the molecular mechanism responsible for T cell senescence in the TME and development of novel strategies to prevent effector T cell senescence are urgently needed for cancer immunotherapy. Methods Senescent T cell populations in the TMEs in mouse lung cancer, breast cancer, and melanoma tumor models were evaluated. Furthermore, T cell senescence induced by mouse tumor and regulatory T (Treg) cells in vitro was determined with multiple markers and assays, including real-time PCR, flow cytometry, and histochemistry staining. Loss-of-function strategies with pharmacological inhibitors and the knockout mouse model were used to identify the potential molecules and pathways involved in T cell senescence. In addition, melanoma mouse tumor immunotherapy models were performed to explore the synergistical efficacy of antitumor immunity via prevention of tumor-specific T cell senescence combined with anti-programmed death-ligand 1 (anti-PD-L1) checkpoint blockade therapy. Results We report that both mouse malignant tumor cells and Treg cells can induce responder T cell senescence, similar as shown in human Treg and tumor cells. Accumulated senescent T cells also exist in the TME in tumor models of lung cancer, breast cancer and melanoma. Induction of ataxia-telangiectasia mutated protein (ATM)-associated DNA damage is the cause for T cell senescence induced by both mouse tumor cells and Treg cells, which is also regulated by mitogen-activated protein kinase (MAPK) signaling. Furthermore, blockages of ATM-associated DNA damage and/or MAPK signaling pathways in T cells can prevent T cell senescence mediated by tumor cells and Treg cells in vitro and enhance antitumor immunity and immunotherapy in vivo in adoptive transfer T cell therapy melanoma models. Importantly, prevention of tumor-specific T cell senescence via ATM and/or MAPK signaling inhibition combined with anti-PD-L1 checkpoint blockade can synergistically enhance antitumor immunity and immunotherapy in vivo. Conclusions These studies prove the novel concept that targeting both effector T cell senescence and exhaustion is an effective strategy and can synergistically enhance cancer immunotherapy.

CD4+ T Cell Exhaustion Leads to Adoptive Transfer Therapy Failure Which Can Be Prevented by Immune Checkpoint Blockade.

Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Abstract 7536: CD4+T cell exhaustion in the tumor microenvironment and antitumor immunity

CD8+ T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy

Reversing T-cell Dysfunction and Exhaustion in Cancer

Tumor-Specific CD4+ T Cells Restrain Established Metastatic Melanoma by Developing Into Cytotoxic CD4– T Cells

Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity

Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion.

Reinvigorating Exhausted CD8+ Cytotoxic T Lymphocytes in the Tumor Microenvironment and Current Strategies in Cancer Immunotherapy

Tumor-Specific CD4<SUP>+</SUP> T Cells Restrain Established Metastatic Melanoma by Developing Into Cytotoxic CD4<SUP>-</SUP> T Cells

Strategies to reinvigorate exhausted CD8+ T cells in tumor microenvironment

The Role of Exhausted T Cells in Tumor

CD8+ T Cell Exhaustion in Cancer

T-cell Exhaustion Interrelates with Immune Cytolytic Activity to Shape the Inflamed Tumor Microenvironment.

Targeting CD4+ T cell Exhaustion to Improve Future Immunotherapy Strategies

T cell exhaustion in human cancers

T cell exhaustion initiates tertiary lymphoid structures and turbocharges cancer-immunity cycle

Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity

Clinical implications of T cell exhaustion for cancer immunotherapy

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy